Galectin-3 is a potential biomarker to insulin resistance and obesity in women with polycystic ovary syndrome
Michelle Teodoro Alves, Isabella D. P. Souza, Cláudia Natália Ferreira, Ana Lúcia Cândido, Mariana Bizzi, Flávia R. Oliveira, Fernando M. Reis, Karina Braga Gomes
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder that affects women in reproductive age. This study aimed to evaluate Gal-3 levels and its role on metabolic parameters in women with PCOS. Gal-3 was measured in 44 PCOS and 25 women recruited as control group for the case-control study. Gal-3 levels were similar between PCOS and control groups (p > 0.05), but showed a positive correlation with glucose levels in the oral glucose tolerance test (OGTT) (r = 0.403, p = 0.037), body mass index (BMI) (r = 0.469, p = 0.027), insulin levels (r = 0.453, p = 0.030) and HOMA-IR (r = 0.738, p = 0.037) in PCOS group. The data suggest that Gal-3 plays a role in the pathophysiology of the insulin resistance and obesity in PCOS group.